Filing Flows

Filing Flows › 8-K events › Zai Lab

Zai Lab: entry into a material definitive agreement

Form 8-K filed Oct 23, 2026 · items 1.01, 3.02, 7.01, 8.01

What the filing says

On October 22, 2026, Zai Lab Limited (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), relating to the sale to the Investors of 11,340,000 American depositary shares

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.02: +0.1% next session across 2,750. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Zai Lab at a glance

Latest quarterQ3 2026
Revenue$108.2M
Revenue Y/Y-7%
Operating margin-58.2%
IndustryPharmaceutical Preparations

Zai Lab, Q3 2026: revenue $108M (-7% year over year), operating margin -58.2%. The chart follows the revenue to costs, profit and cash.

Zai Lab: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.